Rigel Pharmaceuticals published final long-term results from the Phase 1/2 ARROW study of pralsetinib (GAVRETO) in Journal of Clinical Oncology, extending follow-up by an additional 42 months. The update reports robust and durable responses in RET fusion-positive NSCLC with a manageable safety profile. Across evaluable patients with measurable disease (n=259), the company reports an overall response rate of 70%, including 7% complete responses and 63% partial responses. The report also notes no new safety signals and no hypersensitivity reactions in patients receiving prior immunotherapies, while describing three treatment-related deaths in treatment-naive patients in Asia. Clinical investigators highlighted the potential benefit for patients with baseline measurable CNS metastases, while Rigel’s medical leadership positioned the longer-term data as supportive of a first-line treatment role for RET fusion-positive NSCLC patients. For the field, the key question will be how these extended outcomes map to real-world sequencing decisions and future combination strategies.